2nd Edition of the International Obesity and Metabolism Conference (IOMC 2026)
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2nd Edition of the International Obesity and Metabolism Conference (IOMC 2026) — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds
About this event
2nd Edition of the International Obesity and Metabolism Conference (IOMC 2026)
Date: November 18–20, 2026
Venue: Dubai International Conference Centre, Dubai, United Arab Emirates
Event Type: Medical & Scientific Conference, Healthcare & Wellness, Research & Innovation
Estimated Attendance: 2,500+ delegates including researchers, clinicians, dietitians, policymakers, industry leaders, and healthcare professionals
The 2nd Edition of the International Obesity and Metabolism Conference (IOMC 2026) brings together a global community of experts dedicated to addressing the escalating challenges of obesity and metabolic disorders. This premier event will feature cutting-edge research presentations, interactive workshops, and panel discussions led by renowned scientists, physicians, and public health leaders. Attendees will explore innovative therapies, prevention strategies, and multidisciplinary approaches to combat obesity, diabetes, cardiovascular diseases, and related metabolic syndromes.
With a focus on fostering collaboration between academia, industry, and policymakers, IOMC 2026 will highlight advancements in pharmacotherapy, bariatric surgery, nutrigenomics, digital health tools, and lifestyle interventions. The conference will also address global disparities in obesity care, ethical considerations in treatment, and the economic burden of metabolic diseases. Exhibitors from pharmaceutical companies, medical device manufacturers, wellness technology firms, and nutritional product providers will showcase solutions shaping the future of patient care and public health initiatives.
Key highlights include:
- Keynote addresses by Nobel laureates and leading researchers in metabolic health
- Poster sessions and oral presentations of peer-reviewed abstracts
- Industry-sponsored symposia on next-generation therapeutics and diagnostics
- Networking opportunities with decision-makers from 70+ countries
- Workshops on clinical trial design, health policy, and community-based interventions
IOMC 2026 is designed for endocrinologists, cardiologists, primary care physicians, dietitians, geneticists, public health officials, and researchers seeking to translate scientific discoveries into real-world impact. The event will conclude with a call-to-action summit, uniting stakeholders to advocate for systemic changes in obesity prevention and treatment worldwide.
Data sheet
2nd Edition of the International Obesity and Metabolism Conference (IOMC 2026) – Event Attendee & Buyer Profile Analysis
Event date: 17 Jul 2026 – 19 Jul 2026
Location: Village Hotel Changi, Singapore, Singapore
Event status: Upcoming
Research date: 30 Jun 2026
Event Overview
| Event Name | 2nd Edition of the International Obesity and Metabolism Conference (IOMC 2026) |
| Event Date | 17 Jul 2026 – 19 Jul 2026 |
| Event Status | Upcoming |
| Venue | Village Hotel Changi |
| City | Singapore |
| State / Region | Singapore |
| Country | Singapore |
| Organizer | Organizer not publicly confirmed in the supplied materials. |
| Official Event Website | Official event website not supplied for verification. |
| Event Type | Medical & Scientific Conference |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Wellness, Health & Fitness; Science & Research |
| Audience Reach | Likely international scientific and healthcare audience, subject to official confirmation. |
| Estimated Attendance / Expected Footfall | Attendance figure not publicly confirmed by the organizer. |
| Attendance Data Reliability | Low for attendance metrics; core date and venue details based on user-supplied event information. |
| Main Purpose of Event | To convene clinicians, researchers, healthcare providers, public health stakeholders, and industry participants focused on obesity, metabolism, diabetes, nutrition, cardiometabolic health, and related therapeutic, diagnostic, and care-delivery innovations. |
About the Event
The 2nd Edition of the International Obesity and Metabolism Conference (IOMC 2026) is positioned as a specialist medical and scientific meeting focused on obesity, metabolic disorders, nutrition, endocrinology, chronic disease management, and related healthcare research. Based on the event title and supplied description, the conference is likely to attract a multidisciplinary audience including physicians, clinical researchers, dietitians, healthcare administrators, wellness stakeholders, and life-science industry representatives.
From a commercial and partnership perspective, the event is relevant for organizations selling clinical solutions, diagnostics, pharmaceuticals, medical devices, digital therapeutics, research services, nutrition products, hospital technologies, and evidence-based wellness platforms. It is also potentially useful for academic partnerships, clinical trial outreach, KOL engagement, and healthcare market intelligence. However, current-year attendee, sponsor, and exhibitor evidence was not supplied, so buyer targeting should be approached as a mix of conference-led prospecting and broader market-fit outreach rather than a confirmed attendee-list play.
1. Who Attends: Buyers / Attendees
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Endocrinologists and obesity specialists | Hospitals, specialist clinics, academic medical centers | Clinical evaluators, referral influencers, therapy adoption stakeholders | High relevance for therapies, diagnostics, decision-support tools, and treatment pathways |
| Clinical researchers and principal investigators | Universities, research institutes, teaching hospitals | Research collaboration, study design, trial participation, evidence generation | Relevant for CROs, data platforms, laboratory vendors, grants, and academic partnerships |
| Hospital procurement and clinical operations leaders | Public and private hospital groups, care networks | Budget owners or evaluators for devices, patient-monitoring tools, software, nutrition products | Key target group for solution procurement and implementation |
| Pharmaceutical medical and commercial teams | Global and regional pharma companies | Therapy launch planning, medical education, KOL engagement, partnership scouting | High relevance for congress marketing, partnerships, data services, and disease-area platforms |
| Medical device and digital health buyers | Device firms, remote monitoring providers, health-tech companies | Technology scouting, channel partnerships, clinical integration decisions | Strong fit for connected care, metabolic monitoring, telehealth, and adherence solutions |
| Dietitians, nutrition leads, and lifestyle program managers | Hospitals, clinics, wellness providers, community health organizations | Influence protocol adoption, patient education tools, nutritional interventions | Relevant for nutrition brands, behavior-change apps, educational content, and service models |
| Government and public health stakeholders | Health ministries, public hospitals, public health agencies | Policy influence, pilot programs, population health procurement | Relevant for public health tools, screening programs, prevention solutions, and data services |
| Bariatric and metabolic surgery teams | Surgical centers, hospitals, specialty clinics | Clinical and procedural purchasing influence | Relevant for devices, perioperative technologies, patient pathways, and training |
| Association leaders and scientific societies | Medical associations, obesity societies, endocrine societies | Agenda shaping, advocacy, standards, membership partnerships | Useful for thought leadership, sponsorship, co-marketing, and educational alliances |
| Investors and healthcare business development teams | VC firms, corporate strategy teams, healthcare investors | Partnership, funding, market validation, licensing discussions | Relevant for scale-up companies and innovation vendors |
2. Event Location and Attendee Geographic Origin
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Host city: Singapore | Hospital leaders, research institutions, health-tech companies, medical distributors | High | Singapore is a strong regional healthcare, biomedical, and conference hub. |
| Host country: Singapore | Public health systems, academic hospitals, research centers, ministry-linked healthcare entities | High | Likely strong attendance from local clinicians and medical researchers. |
| Nearby ASEAN hubs | Malaysia, Indonesia, Thailand, Philippines, Vietnam healthcare and university delegates | Medium to High | Likely regional draw for obesity, diabetes, and cardiometabolic care stakeholders. |
| Wider Asia-Pacific | Australia, India, China, Japan, South Korea, Hong Kong, Taiwan | Medium | International title suggests broader scientific participation, pending official confirmation. |
| Europe and North America | Speaker faculty, pharma teams, research collaborators, medtech innovators | Medium | Potential participation for scientific exchange and commercial partnership development. |
| Middle East and global medical travel corridors | Specialist clinicians, conference speakers, healthcare investors | Low to Medium | Possible but not verified in supplied materials. |
3. Audience Reach
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification, likely but not fully verified | The event uses “International” in the title and is hosted in Singapore, a common global meeting point for healthcare and scientific events. In the absence of a confirmed delegate-origin breakdown, the most reasonable classification is global with strong Asia-Pacific concentration. |
| Regional | Secondary reach description | ASEAN and broader Asia-Pacific are likely the strongest practical attendee pools for buyer outreach and post-event lead generation. |
4. Sample Buyer Companies and Websites
Current-year attendee, exhibitor, sponsor, or speaker organization lists were not supplied for verification. The organizations below are presented as high-relevance prospecting targets for obesity, metabolism, hospital, research, nutrition, digital health, and life-science outreach in Singapore and the wider region. They should not be treated as confirmed attendees unless official event evidence becomes available.
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| National University Hospital | Academic hospital | Relevant for obesity, endocrinology, metabolic care, research partnerships, and clinical procurement | nuh.com.sg | Head of Endocrinology, Director Clinical Research, Procurement Manager, Innovation Lead | Strong Market Fit, Attendance Not Confirmed |
| Singapore General Hospital | Tertiary hospital | Large clinical buyer and research stakeholder in chronic disease and metabolic health | sgh.com.sg | Clinical Director, Procurement Director, Endocrinologist, Population Health Lead | Strong Market Fit, Attendance Not Confirmed |
| KK Women’s and Children’s Hospital | Specialist hospital | Relevant for maternal, pediatric, nutrition, and metabolic health programs | kkh.com.sg | Department Head, Dietetics Lead, Procurement Manager, Research Manager | Strong Market Fit, Attendance Not Confirmed |
| Tan Tock Seng Hospital | Public hospital | Relevant for chronic disease management, digital health deployment, and patient pathways | ttsh.com.sg | Director Operations, Endocrinology Lead, Clinical Informatics Lead, Procurement Manager | Strong Market Fit, Attendance Not Confirmed |
| National University of Singapore | University / research institution | Relevant for translational research, grants, trial partnerships, and scientific participation | nus.edu.sg | Principal Investigator, Professor, Research Director, Program Manager | Strong Market Fit, Attendance Not Confirmed |
| Duke-NUS Medical School | Medical school / research | Important for scientific faculty, metabolism research, and clinical collaboration | duke-nus.edu.sg | Research Faculty, Program Director, Trial Lead, Academic Partnerships Lead | Strong Market Fit, Attendance Not Confirmed |
| Agency for Science, Technology and Research (A*STAR) | Government research organization | Relevant for biomedical innovation, partnerships, and translational science | a-star.edu.sg | Research Director, Innovation Manager, Partnership Lead, Program Manager | Strong Market Fit, Attendance Not Confirmed |
| Health Promotion Board Singapore | Public health agency | Relevant for prevention, obesity education, screening, and population health campaigns | hpb.gov.sg | Program Director, Public Health Manager, Partnerships Lead, Procurement Officer | Strong Market Fit, Attendance Not Confirmed |
| Ministry of Health Singapore | Government administration | Policy, national care pathways, public-sector healthcare initiatives, and pilot opportunities | moh.gov.sg | Deputy Director, Policy Lead, Program Manager, Procurement Officer | Strong Market Fit, Attendance Not Confirmed |
| Novo Nordisk | Pharmaceutical company | Major obesity and diabetes therapy stakeholder with strong conference relevance | novonordisk.com | Medical Affairs Director, Market Access Lead, Business Development Director, Clinical Partnerships Lead | Strong Market Fit, Attendance Not Confirmed |
| Eli Lilly and Company | Pharmaceutical company | Highly relevant for metabolic disease, diabetes, obesity, and physician engagement | lilly.com | Medical Director, Commercial Director, KOL Manager, Clinical Partnerships Lead | Strong Market Fit, Attendance Not Confirmed |
| Abbott | Diagnostics / nutrition / medtech | Relevant across glucose monitoring, metabolic diagnostics, and nutrition science | abbott.com | Regional Sales Director, Medical Affairs Lead, Diagnostics Partnerships Manager, Category Manager | Strong Market Fit, Attendance Not Confirmed |
5. Job Profiles, Industries and Event Type
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Head of Endocrinology / Obesity Medicine Specialist | Clinical | Director / Head / Senior Physician | Drives therapy adoption, referrals, KOL influence, and clinical evaluation. |
| 2 | Clinical Research Director / Principal Investigator | Research | Director / VP / Faculty | Key for trial participation, publications, data generation, and scientific partnerships. |
| 3 | Procurement Manager | Procurement | Manager / Director | Important for hospital and institution purchasing of equipment, software, diagnostics, and services. |
| 4 | Medical Affairs Director | Medical Affairs | Director / VP | Influences congress strategy, KOL engagement, and clinical evidence positioning. |
| 5 | Director of Clinical Operations | Operations | Director | Owns implementation and workflow integration for patient care and service delivery. |
| 6 | Dietetics Lead / Nutrition Services Manager | Nutrition / Allied Health | Manager / Director | Critical for nutrition protocols, patient education, and wellness solution adoption. |
| 7 | Digital Health / Health Informatics Director | IT / Innovation | Director / Head | Relevant for remote monitoring, patient engagement platforms, and analytics tools. |
| 8 | Public Health Program Manager | Government / Population Health | Manager / Director | Key for prevention initiatives, funding streams, and public-sector partnerships. |
| 9 | Business Development Director | Partnerships / Commercial | Director / VP | Important for partnership sourcing, channel agreements, and strategic alliances. |
| 10 | Category Manager / Sourcing Lead | Procurement / Supply Chain | Manager | Useful where the offer includes consumables, devices, software, nutrition, or outsourced services. |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Hospital & Health Care | Core provider segment for obesity and metabolic care | Clinical solutions, devices, software, patient programs |
| 2 | Pharmaceuticals | Highly relevant for obesity, diabetes, and metabolic therapies | Medical affairs, KOL, congress and partnership outreach |
| 3 | Medical Devices | Fits monitoring, diagnostics, procedural tools, and care devices | Device procurement, hospital pilots, integration |
| 4 | Biotechnology | Supports translational research and pipeline innovation | Research collaborations and therapeutic development |
| 5 | Health, Wellness & Fitness | Relevant for lifestyle intervention and prevention solutions | Weight management programs and digital engagement |
| 6 | Research | Conference likely includes universities and scientific institutes | Grants, trials, studies, evidence partnerships |
| 7 | Higher Education | Medical schools and universities are likely contributors | Faculty outreach and academic collaboration |
| 8 | Government Administration | Public health agencies and ministries may influence policy and programs | Population health and public-sector procurement |
| 9 | Information Technology & Services | Relevant for digital therapeutics, analytics, and telehealth | Platform partnerships and provider implementation |
| 10 | Food & Beverages | Relevant where evidence-based nutrition and reformulation are discussed | Nutrition partnerships and public health initiatives |
| 11 | Food Production | Relevant for medical nutrition and healthier product development | R&D collaboration and policy-aligned product positioning |
| 12 | Nonprofit Organization Management | Patient advocacy and healthcare foundations may participate | Awareness campaigns and community programs |
6. Estimated Attendance
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | Attendance figure not publicly confirmed by the organizer. | Not Confirmed | No official event website, brochure, or registration data supplied | A prior descriptive note mentioned 2,500+ delegates, but that same note conflicts on date and venue and therefore was not treated as reliable current-edition evidence. |
| Exhibitor count | Not publicly confirmed | Not Confirmed | No exhibitor list supplied | Medical conference format may include sponsors and solution providers rather than a large expo floor. |
| Buyer count | Not publicly confirmed | Not Confirmed | No official delegate segmentation supplied | Commercially relevant buyers are likely concentrated in hospitals, pharma, public health, and research institutions. |
| Speaker count | Not publicly confirmed | Not Confirmed | Agenda unavailable for verification | Speaker organizations would materially improve buyer-targeting confidence once published. |
| Sponsor count | Not publicly confirmed | Not Confirmed | No sponsor page supplied | Likely sponsor mix includes pharma, medtech, diagnostics, and nutrition brands. |
| Historical attendance | No reliable prior-year attendance figure verified | Historical / prior-year evidence unavailable | Prior event statistics not supplied | Additional validation needed from official organizer materials. |
7. Key Focus Areas and Buyer Engagement
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Obesity treatment pathways | Better clinical outcomes, evidence-based interventions, treatment adherence | Clinical education, pilot programs, therapy support tools | Pharma support platforms, patient engagement tools, outcome analytics |
| Metabolic disease management | Integrated care for diabetes, cardiovascular risk, and comorbidities | Cross-specialty partnership discussions | Care coordination platforms, diagnostics, monitoring devices |
| Nutrition and lifestyle intervention | Scalable diet and behavior-change programs | Dietitian outreach, institutional program bundling | Medical nutrition, apps, wellness coaching, education content |
| Digital health | Remote engagement, longitudinal tracking, adherence support | Pilot deployments and health-system integration talks | Telehealth, apps, analytics, digital therapeutics |
| Clinical research and trials | Patient recruitment, data quality, biomarker and protocol innovation | PI networking and site partnership outreach | CRO services, data platforms, lab support, real-world evidence tools |
| Public health and prevention | Population-level screening, education, and early intervention | Government and nonprofit partnership development | Campaign tools, screening systems, community program solutions |
| Bariatric and procedural innovation | Safer procedures, patient selection, improved perioperative pathways | Surgeon and hospital equipment discussions | Surgical devices, perioperative software, follow-up care tools |
Lead Quality Assessment
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | High | Good fit for healthcare, medtech, pharma, research, nutrition, and digital-health sellers. |
| Decision-maker availability | Medium | Scientific conferences often include high-value experts and influencers, but not all are direct budget owners. |
| Data collection potential | Medium | Potential rises significantly if speaker, sponsor, agenda, and exhibitor lists become available. |
| Apollo targeting potential | High | Clear targetable industries, departments, and titles exist across hospitals, pharma, universities, and public health. |
| Geographic targeting potential | High | Singapore plus ASEAN provides a manageable and commercially relevant target map. |
| Best outreach approach | Account-based and content-led | Lead with clinical relevance, evidence, pilot value, and partnership logic rather than generic sales messaging. |
| Overall lead quality | High | Strong specialist relevance, but confirmation depth is currently limited. |
| Best use case | Target-account mapping, KOL outreach, sponsor sales, partnership prospecting | Most useful for strategic healthcare outreach rather than pure high-volume attendee-list building at this stage. |
| Limitations / risks | Medium | Lack of verified current-year public participant lists reduces certainty for confirmed attendee targeting. |
Apollo.io Targeting Recommendation
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Hospital & Health Care; Pharmaceuticals; Medical Devices; Biotechnology; Health, Wellness & Fitness; Research; Higher Education; Government Administration; Information Technology & Services; Nonprofit Organization Management | Build the core buyer universe aligned to obesity and metabolic health. |
| Departments | Clinical, Research, Medical Affairs, Procurement, Operations, Innovation, Information Technology, Partnerships, Public Health | Focus on clinical influence plus commercial and operational buying roles. |
| Seniority | Manager, Director, VP, CXO, Head, Partner, Professor | Prioritize decision-makers and senior influencers. |
| Job titles | Endocrinologist, Obesity Specialist, Head of Clinical Research, Principal Investigator, Medical Affairs Director, Procurement Manager, Clinical Operations Director, Dietetics Lead, Public Health Program Manager, Digital Health Director, Business Development Director | Capture clinical, research, buying, and partnership stakeholders. |
| Geography | Singapore first; then Malaysia, Indonesia, Thailand, Philippines, Vietnam, India, Australia, Hong Kong, Japan, South Korea | Reflect likely conference and follow-on regional buyer coverage. |
| Employee size | 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Covers hospitals, pharma, medtech, universities, and public agencies. |
| Keywords | obesity, metabolism, metabolic health, endocrinology, diabetes, bariatric, nutrition, weight management, public health, digital therapeutics, cardiometabolic | Improve relevance for scientific and disease-area specific prospecting. |
| Technologies, if relevant | Remote patient monitoring, EHR/EMR, telehealth, clinical analytics, patient engagement platforms | Useful for digital-health or software suppliers. |
| Revenue range, if relevant | Mid-market to enterprise; public institutions where applicable | Prioritize organizations with budget, research scale, and partnership capacity. |
| Company type | Hospitals, universities, research institutes, pharmaceutical firms, medtech firms, public health agencies, nonprofits | Separates provider, scientific, commercial, and policy-driven account groups. |
Suggested Apollo Search Logic: ("obesity" OR "metabolism" OR "metabolic" OR "endocrinology" OR "diabetes" OR "weight management" OR "bariatric" OR "nutrition" OR "cardiometabolic") AND industry in (Hospital & Health Care, Pharmaceuticals, Medical Devices, Biotechnology, Research, Higher Education, Government Administration) AND seniority in (Manager, Director, VP, Head, CXO) with geography centered on Singapore and ASEAN.
Client Fit Review Required
Please share the client website or product/service details. I will review the client offering and identify the highest-fit buyer companies, Apollo industries, seniority levels, departments, and job titles from this event.
Sources & Verification Notes
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| User-supplied event brief | Provided input | Event title, city, country, venue, start date, and end date | Medium for core logistics supplied by requester |
| Reference description included in request | Provided background text | General thematic scope only | Low for current-edition validation because the reference conflicts with the supplied event date and venue |
| Official event website | Primary source requested | Not supplied for this research pass | Unavailable |
| Organizer website | Primary source requested | Organizer identity not supplied for verification | Unavailable |
| Venue website | Primary source requested | Venue name recorded from supplied brief; independent venue confirmation not completed in this pass | Medium |
This event appears commercially relevant for B2B healthcare prospecting, especially for hospitals, research institutions, pharma, medtech, public health, and digital-health suppliers. It is less suitable for confirmed attendee-list building until official delegate, speaker, sponsor, or exhibitor evidence becomes available.
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to 2nd Edition of the International Obesity and Metabolism Conference (IOMC 2026) — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
🔒 Get my buyer details Free · ~20 seconds